Karin Rosén

5.8k total citations · 5 hit papers
40 papers, 3.7k citations indexed

About

Karin Rosén is a scholar working on Physiology, Rheumatology and Immunology and Allergy. According to data from OpenAlex, Karin Rosén has authored 40 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 19 papers in Rheumatology and 15 papers in Immunology and Allergy. Recurrent topics in Karin Rosén's work include Urticaria and Related Conditions (19 papers), Asthma and respiratory diseases (19 papers) and Allergic Rhinitis and Sensitization (12 papers). Karin Rosén is often cited by papers focused on Urticaria and Related Conditions (19 papers), Asthma and respiratory diseases (19 papers) and Allergic Rhinitis and Sensitization (12 papers). Karin Rosén collaborates with scholars based in United States, Germany and United Kingdom. Karin Rosén's co-authors include Marcus Maurer, Allen P. Kaplan, William W. Busse, Sarbjit S. Saini, Hsin-Ju Hsieh, Nicola A. Hanania, Janice Canvin, Thomas B. Casale, Benjamin Trzaskoma and Dennis A. Wong and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Karin Rosén

40 papers receiving 3.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

2013 714 citations Marcus Maurer, Karin Rosén et al. New England Journal of Medicine profile →
Exploring the Effects of Omalizumab in Allergic Asthma

2013 669 citations Nicola A. Hanania, Sally E. Wenzel et al. American Journal of Respiratory and Critical Care Medicine profile →
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

2011 429 citations Nicola A. Hanania, Oral Alpan et al. profile →
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

2013 392 citations Allen P. Kaplan, Dennis K. Ledford et al. Journal of Allergy and Clinical Immunology profile →
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

2014 307 citations Sarbjit S. Saini, Carsten Bindslev‐Jensen et al. Journal of Investigative Dermatology profile →

Peers

Countries citing papers authored by Karin Rosén

Since Specialization

Citations

This map shows the geographic impact of Karin Rosén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Rosén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Rosén more than expected).

Fields of papers citing papers by Karin Rosén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Rosén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Rosén. The network helps show where Karin Rosén may publish in the future.

Co-authorship network of co-authors of Karin Rosén

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Rosén. A scholar is included among the top collaborators of Karin Rosén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Rosén. Karin Rosén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	INCREASED INCIDENCE AND PREVALENCE OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS IN THE UNITED STATES 2018 ·Annals of Allergy Asthma & Immunology ·Phil Lieberman, J. Wesley Sublett, Yaser Ali, Tmirah Haselkorn, (unknown), (unknown), Karin Rosén, Todd A. Mahr	15
2	Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life 2017 ·The Journal of Allergy and Clinical Immunology In Practice ·Bradley E. Chipps, Tmirah Haselkorn, Karin Rosén, David R. Mink, Benjamin Trzaskoma, Allan T. Luskin	25
3	Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience 2017 ·Journal of Allergy and Clinical Immunology ·Bradley E. Chipps, Bob Lanier, Henry Milgrom, A. Deschildre, Gunilla Hedlin, Stanley J. Szefler, Meyer Kattan, Farid Kianifard, Benjamin Ortiz, Tmirah Haselkorn, Ahmar Iqbal, Karin Rosén, Benjamin Trzaskoma, William W. Busse	115
4	Baseline Blood Eosinophils and Reduction of Asthma Exacerbations By Omalizumab in Children with Moderate-to-Severe Allergic Asthma 2017 ·Journal of Allergy and Clinical Immunology ·Stanley J. Szefler, Thomas B. Casale, Karin Rosén, Benjamin Trzaskoma, Tmirah Haselkorn, Benjamin Ortiz, William W. Busse	2
5	A randomized multicenter study evaluating Xolair persistence of response after long-term therapy 2016 ·Journal of Allergy and Clinical Immunology ·Dennis K. Ledford, William W. Busse, Benjamin Trzaskoma, Theodore A. Omachi, Karin Rosén, Bradley E. Chipps, Allan T. Luskin, Paul G. Solari	146
6	Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies 2016 ·Annals of Allergy Asthma & Immunology ·James L. Zazzali, Allen P. Kaplan, Marcus Maurer, Karina Raimundo, Benjamin Trzaskoma, Paul G. Solari, Evgeniya Antonova, Meryl H. Mendelson, Karin Rosén	20
7	Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies 2016 ·Clinical and Translational Allergy ·Ana M. Giménez‐Arnau, Sheldon L. Spector, Evgeniya Antonova, Benjamin Trzaskoma, Karin Rosén, Theodore A. Omachi, Donald E. Stull, Maria‐Magdalena Balp, Thomas Murphy	25
8	The minimal important difference for measures of urticaria disease activity: Updated findings 2015 ·Allergy and Asthma Proceedings ·Susan D. Mathias, Ross D. Crosby, Karin Rosén, James L. Zazzali	19
9	Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy 2015 ·The Journal of Allergy and Clinical Immunology In Practice ·Thomas B. Casale, Jonathan A. Bernstein, Marcus Maurer, Sarbjit S. Saini, Benjamin Trzaskoma, Hubert Chen, Clive Grattan, Ana M. Giménez‐Arnau, Allen P. Kaplan, Karin Rosén	64
10	Evaluating omalizumab persistency of response after long-term therapy (XPORT) 2014 ·European Respiratory Journal ·William W. Busse, (unknown), Theodore A. Omachi, Janice Canvin, Karin Rosén, Bradley E. Chipps, Allan T. Luskin, Paul G. Solari	9
11	Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab 2014 ·Journal of Allergy and Clinical Immunology ·Aidan A. Long, Abdelkader Rahmaoui, Kenneth J. Rothman, Eva C. Guinan, Mark D. Eisner, Mary S. Bradley, Carlos Iribarren, Hubert Chen, Gillis Carrigan, Karin Rosén, Stanley J. Szefler	150
12	Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study breakdown → 2014 ·Journal of Investigative Dermatology ·Sarbjit S. Saini, Carsten Bindslev‐Jensen, Marcus Maurer, Jean‐Jacques Grob, Emel Bülbül Başkan, Mary S. Bradley, Janice Canvin, Abdelkader Rahmaoui, Panayiotis Georgiou, Oral Alpan, Sheldon L. Spector, Karin Rosén	307
13	Estimating The Minimal Important Difference (MID) Of The Measures In The Urticaria Patient Daily Diary (UPDD): Updated Findings Using Data From The Asteria I, Asteria II, and Glacial Studies Of Omalizumab In Chronic Idiopathic/Spontaneous Urticaria 2014 ·Journal of Allergy and Clinical Immunology ·Susan D. Mathias, Ross D. Crosby, Karin Rosén, James L. Zazzali	2
14	Exploring the Effects of Omalizumab in Allergic Asthma breakdown → 2013 ·American Journal of Respiratory and Critical Care Medicine ·Nicola A. Hanania, Sally E. Wenzel, Karin Rosén, Hsin-Ju Hsieh, Sofia Mosesova, David F. Choy, Preeti Lal, Joseph R. Arron, Jeffrey M. Harris, William W. Busse	669
15	Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy 2013 ·The AAPS Journal ·Rui Zhu, Yanan Zheng, Wendy S. Putnam, Jennifer Visich, Mark D. Eisner, John G. Matthews, Karin Rosén, David Z. D’Argenio	9
16	Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy breakdown → 2013 ·Journal of Allergy and Clinical Immunology ·Allen P. Kaplan, Dennis K. Ledford, Mark Ashby, Janice Canvin, James L. Zazzali, Edward Conner, Joachim Veith, Nikhil Kamath, Petra Staubach, Thilo Jakob, Rob G. Stirling, Piotr Kuna, William Berger, Marcus Maurer, Karin Rosén	392
17	Baseline Characteristics of Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Enrolled in a Phase III, Randomized, Placebo-Controlled Trial of Omalizumab 2013 ·Journal of Allergy and Clinical Immunology ·Karin Rosén, Hsin-Ju Hsieh, Panayiotis Georgiou, Thomas B. Casale, Marcus Maurer	1
18	Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria breakdown → 2013 ·New England Journal of Medicine ·Marcus Maurer, Karin Rosén, Hsin-Ju Hsieh, Sarbjit S. Saini, Clive Grattan, Ana M. Giménez‐Arnau, Sunil Agarwal, Ramona L. Doyle, Janice Canvin, Allen P. Kaplan, Thomas B. Casale	714
19	A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria 2011 ·Journal of Allergy and Clinical Immunology ·Sarbjit S. Saini, Karin Rosén, (unknown), Dennis A. Wong, Edward Conner, Allen P. Kaplan, Sheldon L. Spector, Marcus Maurer	268
20	Development of a daily diary for patients with chronic idiopathic urticaria 2010 ·Annals of Allergy Asthma & Immunology ·Susan D. Mathias, Stephen C. Dreskin, Allen P. Kaplan, Sarbjit S. Saini, Sheldon L. Spector, Karin Rosén	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact